Last reviewed · How we verify
Sodium Laural Sulfate
Sodium Laural Sulfate is a Small molecule drug developed by Stiefel, a GSK Company. It is currently in Phase 1 development.
At a glance
| Generic name | Sodium Laural Sulfate |
|---|---|
| Sponsor | Stiefel, a GSK Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Laural Sulfate CI brief — competitive landscape report
- Sodium Laural Sulfate updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI
Frequently asked questions about Sodium Laural Sulfate
What is Sodium Laural Sulfate?
Sodium Laural Sulfate is a Small molecule drug developed by Stiefel, a GSK Company.
Who makes Sodium Laural Sulfate?
Sodium Laural Sulfate is developed by Stiefel, a GSK Company (see full Stiefel, a GSK Company pipeline at /company/stiefel-a-gsk-company).
What development phase is Sodium Laural Sulfate in?
Sodium Laural Sulfate is in Phase 1.
Related
- Manufacturer: Stiefel, a GSK Company — full pipeline
- Compare: Sodium Laural Sulfate vs similar drugs
- Pricing: Sodium Laural Sulfate cost, discount & access